Aqemia, a Paris, France-based pharmatech company, raised €30M in Series A funding.
The round was led by Eurazeo and Bpifrance with the participation from Elaia.
The company intends to use the funds to scale drug discovery and its proprietary therapeutic assets pipeline, with a first emphasis on oncology and immuno-oncology.
Co-founded by Maximilien Levesque (CEO) and Emmanuelle Martiano (COO), Aqemia is a pharmatech company generating a drug discovery pipeline on a mission to design drug candidates for dozens of critical diseases. Unlike AI-based platforms that need experimental data to train on, Aqemia addresses drug discovery projects from their earliest stage by generating its own data using quantum physics algorithms derived from 12 years of research at univ. Cambridge and Oxford (UK), and École Normale Supérieure and CNRS.
FinSMEs
19/10/2022